[go: up one dir, main page]

CO2021014694A2 - Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio - Google Patents

Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio

Info

Publication number
CO2021014694A2
CO2021014694A2 CONC2021/0014694A CO2021014694A CO2021014694A2 CO 2021014694 A2 CO2021014694 A2 CO 2021014694A2 CO 2021014694 A CO2021014694 A CO 2021014694A CO 2021014694 A2 CO2021014694 A2 CO 2021014694A2
Authority
CO
Colombia
Prior art keywords
prevention
treatment
respiratory tract
tract infection
subunit vaccine
Prior art date
Application number
CONC2021/0014694A
Other languages
English (en)
Inventor
Andreas Meinke
Fabien Perugi
Klaus Schwamborn
Wolfgang Schüler
Urban Lundberg
Original Assignee
Valneva Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Valneva Se filed Critical Valneva Se
Publication of CO2021014694A2 publication Critical patent/CO2021014694A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18311—Metapneumovirus, e.g. avian pneumovirus
    • C12N2760/18334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a proteínas F de hMPV modificadas estabilizadas en la conformación prefusión como candidatos a vacuna.
CONC2021/0014694A 2019-05-20 2021-10-29 Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio CO2021014694A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19175413 2019-05-20
PCT/EP2020/063973 WO2020234300A1 (en) 2019-05-20 2020-05-19 A subunit vaccine for treatment or prevention of a respiratory tract infection

Publications (1)

Publication Number Publication Date
CO2021014694A2 true CO2021014694A2 (es) 2022-01-17

Family

ID=66685352

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0014694A CO2021014694A2 (es) 2019-05-20 2021-10-29 Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio

Country Status (20)

Country Link
US (2) US12162907B2 (es)
EP (1) EP3972639A1 (es)
JP (1) JP2022533318A (es)
KR (1) KR20220010478A (es)
CN (1) CN114127101A (es)
AU (1) AU2020277661A1 (es)
BR (1) BR112021021637A2 (es)
CA (1) CA3138064A1 (es)
CL (1) CL2021002819A1 (es)
CO (1) CO2021014694A2 (es)
EC (1) ECSP21079178A (es)
GB (1) GB2598494B (es)
IL (1) IL287099A (es)
MX (1) MX2021013111A (es)
PE (1) PE20220400A1 (es)
PH (1) PH12021552736A1 (es)
SA (1) SA521430813B1 (es)
SG (1) SG11202110646PA (es)
WO (1) WO2020234300A1 (es)
ZA (1) ZA202106883B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8986704B2 (en) 2012-07-06 2015-03-24 Valneva Austria Gmbh Mutant fragments of OspA and methods and uses relating thereto
CA3059817A1 (en) 2017-04-13 2018-10-18 Valneva Austria Gmbh Multivalent ospa polypeptides and methods and uses relating thereto
BR112021021637A2 (pt) 2019-05-20 2021-12-21 Valneva Se Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
CA3174599A1 (en) 2020-04-09 2021-10-14 Robert Schlegl Improvements in vaccine formulations for medical use
IL301950A (en) 2020-10-09 2023-06-01 Univ Texas Prefusion-stabilized hmpv f proteins
EP4243865A1 (en) 2020-11-13 2023-09-20 Icosavax, Inc. Protein-based nanoparticle vaccine for metapneumovirus
CA3210412A1 (en) 2021-04-09 2022-10-13 Urban Lundberg Human metapneumo virus vaccine
WO2023110618A1 (en) * 2021-12-16 2023-06-22 Janssen Vaccines & Prevention B.V. Stabilized pre-fusion hmpv fusion proteins
US20240252614A1 (en) 2023-01-18 2024-08-01 Pfizer Inc. Vaccines against respiratory diseases
WO2024167866A2 (en) * 2023-02-06 2024-08-15 Cyanvac Llc Modified piv5 vaccine vectors: methods of making and uses

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5547871A (en) 1993-01-25 1996-08-20 American Cyanamid Company Heterologous signal sequences for secretion of insect controlling proteins
PT772619E (pt) 1994-07-15 2006-10-31 Univ Iowa Res Found Oligonucleotidos imunomoduladores
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
MXPA02012010A (es) 2000-06-08 2005-04-22 Intercell Biomedizinishce Fors Oligodesoxinucleotidos inmunoestimulantes.
AU8981301A (en) 2000-08-17 2002-02-25 Cistem Biotechologies Gmbh A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
US8715922B2 (en) * 2001-01-19 2014-05-06 ViroNovative Virus causing respiratory tract illness in susceptible mammals
ES2288555T3 (es) 2001-05-21 2008-01-16 Intercell Ag Moleculas de oligodesoxinucleotidos inmunoestimuladores.
EP1450821A1 (en) 2001-12-07 2004-09-01 Intercell AG Immunostimulatory oligodeoxynucleotides
WO2004084938A1 (en) 2003-03-24 2004-10-07 Intercell Ag Improved vaccines
WO2004096993A2 (en) * 2003-04-25 2004-11-11 Medimmune Vaccines, Inc. Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences and methods for propagating virus
MX2012000036A (es) 2009-06-24 2012-02-28 Glaxosmithkline Biolog Sa Vacuna.
US20120315270A1 (en) 2009-10-21 2012-12-13 The United States Of America, As Represented By The Rsv immunogens, antibodies and compositions thereof
CN102145167A (zh) * 2010-02-05 2011-08-10 重庆医科大学附属儿童医院 重组人类偏肺病毒疫苗
BR112012029912A2 (pt) 2010-05-26 2016-11-16 Selecta Biosciences Inc vácinas de combinação de nanotransportadores sintéticos
FI3785730T3 (fi) 2011-12-06 2024-05-06 Valneva Austria Gmbh Alumiiniyhdisteet terapiassa ja rokotteissa käyttöä varten
CL2013002829A1 (es) 2013-10-01 2014-04-04 Univ Pontificia Catolica Chile Formulacion inmunogenica que contiene bcg vivas recombinantes que expresan antigenos de metapneumovirus (hmpv) en una suspension que se prepara a partir de un liofilizado sin la necesidad de adjuvante; su uso farmaceutico; vacuna contra hmpv.
US10420834B2 (en) * 2014-12-24 2019-09-24 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant metapneumovirus F proteins and their use
ES2922760T3 (es) 2015-10-22 2022-09-20 Modernatx Inc Vacunas de virus respiratorios
US10961283B2 (en) 2016-06-27 2021-03-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Self-assembling insect ferritin nanoparticles for display of co-assembled trimeric antigens
WO2019092002A1 (en) * 2017-11-07 2019-05-16 Valneva Se Pharmaceutical compositions for treatment or prevention of viral infections
BR112021021637A2 (pt) 2019-05-20 2021-12-21 Valneva Se Vacina de subunidade para tratamento ou prevenção de uma infecção do trato respiratório
CA3210412A1 (en) 2021-04-09 2022-10-13 Urban Lundberg Human metapneumo virus vaccine

Also Published As

Publication number Publication date
ECSP21079178A (es) 2021-11-30
BR112021021637A2 (pt) 2021-12-21
WO2020234300A1 (en) 2020-11-26
MX2021013111A (es) 2021-11-17
US20240067681A1 (en) 2024-02-29
GB2598494A (en) 2022-03-02
JP2022533318A (ja) 2022-07-22
AU2020277661A1 (en) 2021-10-21
KR20220010478A (ko) 2022-01-25
CA3138064A1 (en) 2020-11-26
SG11202110646PA (en) 2021-10-28
ZA202106883B (en) 2022-07-27
GB202114836D0 (en) 2021-12-01
GB2598494B (en) 2024-07-24
PE20220400A1 (es) 2022-03-22
US20220185847A1 (en) 2022-06-16
SA521430813B1 (ar) 2024-04-27
CN114127101A (zh) 2022-03-01
CL2021002819A1 (es) 2022-07-08
US12162909B2 (en) 2024-12-10
IL287099A (en) 2021-12-01
EP3972639A1 (en) 2022-03-30
PH12021552736A1 (en) 2022-07-11
US12162907B2 (en) 2024-12-10

Similar Documents

Publication Publication Date Title
CO2021014694A2 (es) Una vacuna de subunidad para el tratamiento o la prevención de una infección del tracto respiratorio
AR118371A2 (es) Procedimiento para la preparación de n-[(3-aminooxetan-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-quinazolin-4-amina
CU20150096A7 (es) Compuestos de amida y composición farmacéutica para el tratamiento de vih
BR112017005917A2 (pt) processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana
CU24117B1 (es) Derivados de la piridina de tieno (2,3-b) como inhibidores virales de la réplica
PE20151867A1 (es) Polipeptidos f de prefusion del virus sincicial respiratorio (rsv )solubles y estabilizados
UA116999C2 (uk) Виділене антитіло до гемаглютиніну та фармацевтична композиція, що його містить
BR112014018990A8 (pt) Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção
CO6960552A2 (es) Compuestos de (hetero)arilciclopropilamina como inhibidores de lsd1
BR112015003188A2 (pt) Composto, composição farmacêutica, uso do composto e método para tratar uma doença ou condição mediada por rorgammat em um paciente
CR20110509A (es) Composicion farmaceutica
UY36905A (es) Anticuerpos neutralizantes de poliomavirus
BR112020008664A8 (pt) Composto macrocíclico que atua como inibidor de weel e aplicações do mesmo
CU20170109A7 (es) Derivado de quinoleina para tratar y prevenir infecciones virales
ES2510940R1 (es) Composición farmacéutica combinada y su uso para preparar un medicamento destinado al tratamiento y prevención de las enfermedades infecciosas
CY1118399T1 (el) Ενωσεις βενζοφουρανιου για την θεραπεια μολυνσεων ιου ηπατιτιδας c
UY36145A (es) Compuestos de 1, 3, 4-tiadiazol y uso de los mismos para el tratamiento del cáncer
CR20170113A (es) Composiciones farmacéuticas de acción prolongada
DOP2016000170A (es) Compuestos derivados de hidroxiformamida y usos del mismo
ES2524385R1 (es) Composición farmacéutica y su uso para preparar un medicamento destinado al tratamiento y la prevención de enfermedades causadas por el VIH
CO2020008887A2 (es) Inhibidores de pi4kiiiβ
BR112018067554A2 (pt) formulações de testosterona e métodos de tratamento com as mesmas
BR112019005456A2 (pt) composição farmacêutica e método para tratamento de esteatose hepática não alcoólica
CL2017001161A1 (es) Composiciones farmacéuticas de acción prolongada para la hepatitis c
CL2017001160A1 (es) Combinación de composiciones de acción prolongada y métodos para la hepatitis c